ArticleJournal of clinical apheresis2025
Therapeutic Plasma Exchange After Spontaneous Intracranial Hemorrhage for a Patient With Antiphospholipid Syndrome and Lupus Anticoagulant Hypoprothrombinemia.
Article in Journal of clinical apheresis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Therapeutic Plasma Exchange After Spontaneous Intracranial Hemorrhage for a Patient With Antiphospholipid Syndrome and Lupus Anticoagulant Hypoprothrombinemia.Journal of clinical apheresis · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antiphospholipid syndrome (APS) is characterized by the presence of antiphospholipid antibodies (aPL), macro- and micro-vascular thromboembolic complications. Lupus anticoagulant-hypoprothrombinemia (LAHPS) may confound the diagnosis and management of bleeding. Catastrophic APS has a category 1 indication for therapeutic plasma exchange (TPE). However, in patients with APS, LAHPS, and intracranial hemorrhage (ICH), TPE is not well described. A 47-year-old man with known APS anticoagulated on warfarin was transferred for diffuse spontaneous subdural hemorrhages (SDH) with somnolence. aPL levels were elevated on presentation; anti-β2-glycoprotein-I antibody (aβ2GPI) IgG was higher than the reportable range. Factor II activity level was 20% despite holding warfarin: concerning for LAHPS. TPE was initiated to minimize risk of thromboembolism while holding anticoagulation. Level of consciousness improved by the second TPE. An acute lacunar infarct was detected on MRI, but this may have occurred before initiating TPE. Measures of lupus anticoagulant and anticardiolipin (aCL) IgG decreased initially, but aβ2GPI IgG remained above the reportable range. Both aCL and aβ2GPI IgM titers increased initially but decreased by day 31. Factor II activity level improved but remained below normal. Serial imaging showed resolution of SDH without new infarction. In patients with APS and recurrent thromboembolic disease, assessment and treatment of ICH may be confounded by LAHPS. Reversal of anticoagulation is reserved for patients in extremis, and treatment of LAHPS has previously been associated with thrombosis. In this context, TPE may be considered in combination with steroids and rituximab to bridge overlapping thromboembolic and hemorrhagic risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.